Namita Chittoria, MD

Biography

Last Updated: 01/16/2024Namita Chittoria, MD     University of UtahSchool of MedicineOncologyCONTACT INFORMATIONHuntsman Cancer InstituteMedical Oncology2000 Circle Of Hope, KFKSalt Lake City, UT 84112801-213-8473 (phone)801-585-0124 (fax)[email protected]          EDUCATIONYearsDegreeInstitution (Area of Study)2012 - 2013FellowCleveland Clinic Foundation (Experimental Therapeutics)    Cleveland, OH2010 - 2012FellowUniversity of Texas Health Science Center (Medical Oncology)    San Antonio, TX2009 - 2010FellowUniversity at Buffalo (Palliative Medicine and Hospice)    Buffalo, NY2006 - 2009ResidentSUNY Upstate Medical University (Internal Medicine)    Syracuse, NY2002 - 2005ResidentKing George’s Medical University (Internal Medicine)    Lucknow, India1996 - 2001M.B.B.S.King George’s Medical University (Medicine)    Lucknow, India     BOARD CERTIFICATIONS11/13/2013 - 12/31/2023American Board of Internal Medicine (Sub: Medical Oncology), Certified08/24/2009 - 12/31/2019American Board of Internal Medicine               RESEARCH INTERESTSTriple Negative Breast Cancer     UNIVERSITY OF UTAH ACADEMIC HISTORYInternal Medicine (Oncology), 09/03/2019 - Present09/03/2019 - PresentAssistant Professor (Clinical)          PROFESSIONAL EXPERIENCE     Full-Time Positions 2019 - PresentAssistant Profesor, University of Utah, Salt Lake City, UT     2017 - 2019Medical Oncologist, Intermountain Health Care, McKay Dee Hospital, Layton Hospital & Ogden, UT     2013 - 2017Assistant Professor, SUNY Upstate Medical University, Syracuse, NY  Responsibilities:• Breast Cancer clinic and inpatient consults (11/2014 – 06/2016)• Teaching and supervision of fellows, residents and medical students2013 - 2017Staff Physician, Cancer Center, Syracuse VA Medical Center, Syracuse, NY  Responsibilities:• Outpatient continuity clinics (emphasizing GU malignancies) and inpatient consults• Lead Oncology research program- VA Site Principal Investigator for Alliance in Clinical Trials for Oncology     HONORS AND AWARDS2013Merit Award, American Society of Clinical Oncology Annual Meeting, Chicago, IL2012Chosen to be a participant, ASCO/AACR Workshop: Methods in Clinical Cancer Research, Vail, CO                                        SERVICE AT PREVIOUS INSTITUTIONS2013 - 2017Member, Syracuse VA Medical Center, GU and Thoracic Tumor Board, held every 2 weeks2013 - 2017Member, Syracuse VA Medical Center, Transfusion Committee, to oversee safety, AAAB compliance, appropriateness and accessibility of blood product support2013 - 2017Member, Syracuse VA Medical Center, Cancer Committee, to oversee integrated activities of Pharmacy, Palliative Care, Nursing, Pain Management, Women’s Health, Quality Control, Radiation Oncology, and Research activitiesADDITIONAL SERVICE CONTRIBUTIONS2023 - PresentGilead Science Advisory Board2022 - PresentImpediMed Oncology Advisory Board                 FUNDING               Past Contracts10/19/16 - 07/30/18SWOG S1416 A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.    Principal Investigator(s): Namita Chittoria  Role: Principal Investigator09/08/20 - 07/27/21CytoDyne  Principal Investigator(s): Namita Chittoria  Role: Principal Investigator08/25/17 - 03/29/21Alliance Foundation AFT-38 PATINA          Principal Investigator(s): Namita Chittoria  Role: Principal Investigator     CLINICAL STUDIES2023 - PresentRandomized, Open-Label, Phase III Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L12022 - PresentPhase II, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Nab-Paclitaxel or Paclitaxel versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients with Metastatic Triple-Negative Breast Cancer.2020 - PresentA Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer.  2020 - PresentPhase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer          TEACHING RESPONSIBILITIES/ASSIGNMENTS     Mentoring/AdvisingFellow2013 - 2016Member, Research Committee, SUNY Upstate Medical University, for fellows in training (mentor of two fellows)                    PEER-REVIEWED JOURNAL ARTICLES1.Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239.2.Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N (2019). Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urol Oncol, 2019 Jun;37((6)), 352.e19-352.e24..3.Chittoria N, Haddad H, Elson P, Tannir NM, Wood LS, Dreicer R, Garcia JA, Rini BI, Jonasch E (2016). Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer, 16, 254.4.Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee J-L, Srinivas S, Knox JK, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, Apr13((2)), e79-85.5.Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI (2015). Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer, 13(2), e79-85.6.Miraj R, Chittoria N, Mehta P, Murthy U (2007). Heat Stress and Exercise-Induced Ischemic Colitis in a 21 Year Old. Am J Gastroenterol, (S2), s351.     OTHER PUBLICATIONSCase Reports1.Basnet A, Khullar G, Mehta R, Chittoria N (2017). A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab. Clin Genitourin Cancer, 15(5), e881-e884.                         Pedagogical Publications1.Chittoria N, Rini BI (2012). Renal Cell Carcinoma [Web], Cleveland, OH: The Disease Management Project, Carey WD (eds). Available: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/.                 PUBLISHED ABSTRACTS1.Cristofanilli M, Chittoria N, Ehsani S, Rui H, Dolezal M, Stork-Sloots L, de Snoo F, Recknor C, Abramson V (2022). A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC) Abstract P5-17-08 [Abstract]., 84(4_suppl).2.Rini BI, Wood LS, Elson P, Zhu H, Chittoria N, Mittal K, Dreicer R, Gilligan TD, Shah SN, Garcia JA (2013). A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC) [Abstract]. Journal of Clinical Oncology, 31 (15_suppl), 4515.3.Rajan A, Tolocica I, El-Zammar O, Chittoria N, Singh M, Newman N, Gajra A (2008). mTOR Expression in Pancreatic Adenocarcinoma and its Correlation with Survival [Abstract]. J Clin Oncol , (20 suppl), 22169.